Search Results - alzheimer%27s+disease

14 Results Sort By:
Compounds and methods to target transmembrane domain of membrane proteins (e.g., APPTM) to inhibit intramembrane proteolysis
RPI ID: 2019-075-401, 2019-076-601 Innovation Summary: A substrate-specific inhibitor is proposed to block γ-secretase cleavage of amyloid precursor protein (APP), aiming to reduce amyloid-β (Aβ) production without affecting other physiological substrates. Unlike broad-spectrum γ-secretase inhibitors that target presenilin directly,...
Published: 3/10/2026   |   Inventor(s): Chunyu Wang
Keywords(s): Alzheimer's disease, amyloid, amyloid precursor protein, anti-Abeta, C99, gamma-secretase, intramembrane proteolysis, Notch, transmembrane domain of APP
Category(s): Biotechnology and the Life Sciences
Alpha Assay to Screen for Inhibitor Protein-Glycan Interactions in Neurodegeneration
RPI ID: 2024-030-201 Innovation Summary: This technology introduces a bead-based assay platform designed to screen for inhibitors of protein-glycan interactions implicated in neurodegenerative diseases. The assay utilizes functionalized beads to capture glycan-binding proteins and assess their interaction dynamics in the presence of candidate inhibitors....
Published: 3/10/2026   |   Inventor(s): Chunyu Wang, Shannon Faris
Keywords(s): AlphaScreen, Alzheimer's disease, Drug Discovery, heparan sulfate proteoglycan (HSPG), Heparin, tau, tauopathies
Category(s): Biotechnology and the Life Sciences
Reagents Targeting Neurodegenerative Diseases and Traumatic Brain Injury
Misfolding and aggregation of proteins, such as beta-amyloid (Aß), alpha-synuclein (a-syn), tau and TAR DNA-binding protein 43 (TDP-43), have been strongly correlated with early onset of neurodegenerative diseases such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Frontotemporal Dementia (FTD), amyotrophic lateral sclerosis (ALS) and...
Published: 2/26/2026   |   Inventor(s): Michael Sierks, Stephanie Williams
Keywords(s): Alzheimer's Disease, Bioassay, biomarker, Neurodegenerative Disorders, Neurological Disorders
Category(s): Bioanalytical Assays, Chemistries & Devices, Diagnostic Assays/Devices, Life Science (All LS Techs), Neurodegenerative Disease Technologies, Proteomic Assays/Reagents/Tools, Non-Cancer Therapeutics
Reagents Targeting Neurodegenerative Diseases and Traumatic Brain Injury
Misfolding and aggregation of proteins, such as beta-amyloid (Aß), alpha-synuclein (a-syn), tau and TAR DNA-binding protein 43 (TDP-43), have been strongly correlated with early onset of neurodegenerative diseases such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Frontotemporal Dementia (FTD), amyotrophic lateral sclerosis (ALS) and...
Published: 2/26/2026   |   Inventor(s): Michael Sierks, Lalitha Venkataraman, Wei Xin
Keywords(s): Alzheimer's Disease, CNS Therapeutics, Dementias, Neurodegenerative Disorders, Neurological Disorders, Phage display
Category(s): Bioanalytical Assays, Chemistries & Devices, Diagnostic Assays/Devices, Life Science (All LS Techs), Neurodegenerative Disease Technologies, Non-Cancer Therapeutics, Proteomic Assays/Reagents/Tools
Modulating Molecular Chaperone DnaJB6b as a Novel Method to Regulate Tau Seeding and Propagation
­Advantages: Semi-high throughput screening accelerates drug discovery by quickly identifying candidates, reducing time to market, and gaining a competitive edge. Molecular Chaperone reduces tau aggregation, preserving cognitive function and improving patient quality. Employs a precision medicine approach targeting tauopathy mechanisms, potentially...
Published: 10/14/2025   |   Inventor(s): Abigail Esquivel, Laura Blair
Keywords(s): Alzheimer's Disease, Neurodegenerative Diseases
Category(s): Technology Classifications > Medical > Neuroscience, Technology Classifications > Medical > Biotechnology, Technology Classifications > Medical > Therapeutics
Novel Helical Peptodomimetics that Prevent the Formation of Aβ Oligomerization in Alzheimer’s Disease (AD)
­Advantages: Developed sulfonyl-γ-AA peptide helical peptidomimetics that can prevent the formation of neurotoxic Aβ oligomerization. High Specificity: The lead sulfonyl-γ-AApeptide helical foldamer, Ab-6, exhibits precise targeting to the central region of Aβ42 and induces α-helix conformation in Aβ. Sequence-Specific...
Published: 9/10/2025   |   Inventor(s): Jianfeng Cai, Heng Liu
Keywords(s): Alzheimer's Disease, Biotechnology, Neurodegenerative Diseases
Category(s): Technology Classifications > Medical > Biomedical Engineering, Technology Classifications > Medical > Biotechnology, Technology Classifications > Medical > Neuroscience
Methylene Blue and Methylene Violet Analogs as Mitochondrial Therapeutic Agents
Mitochondrial dysfunction has been implicated in a number of diseases, including Alzheimer’s disease (AD), movement disorders, diseases of the cardiovascular system, cancer, diabetes, blindness and deafness. Mitochondrial defects are damaging, particularly to tissues with high energy demands such as neural and muscle tissues. Membrane-penetrating...
Published: 2/26/2026   |   Inventor(s): Sidney Hecht, Omar Khdour, Sandipan Roy Chowdhury, Nishant Visavadiya
Keywords(s): Alzheimer's Disease, Diabetes, Genetic Disorders, Metabolic Disorders, Mitochondrial medicine
Category(s): Life Science (All LS Techs), Non-Cancer Therapeutics, Pharmaceuticals
Methylene Blue and Methylene Violet Analogs as Mitochondrial Therapeutic Agents
Mitochondrial dysfunction has been implicated in a number of diseases, including Alzheimer’s disease (AD), movement disorders, diseases of the cardiovascular system, cancer, diabetes, blindness and deafness. Mitochondrial defects are damaging, particularly to tissues with high energy demands such as neural and muscle tissues. Membrane-penetrating...
Published: 2/26/2026   |   Inventor(s): Sidney Hecht, Omar Khdour, Sandipan Roy Chowdhury, Indrajit Bandyopadhyay
Keywords(s): Alzheimer's Disease, Diabetes, Genetic Disorders, Metabolic Disorders, Mitochondrial medicine, Neurodegenerative Disorders, Parkinson's Disease, Pharmaceutical
Category(s): Life Science (All LS Techs), Non-Cancer Therapeutics, Pharmaceuticals
Multifunctional Radical Quenchers for Mitochondrial Diseases
Mitochondrial diseases are a group of disorders associated with dysfunctional mitochondria, often caused by genetic mutations to mitochondrial DNA. Mitochondrial defects are damaging, particularly to tissues with high energy demands such as neural and muscle tissues. Energy effecting defects have been implicated in forms of movement disorders, cardiomyopathy,...
Published: 2/26/2026   |   Inventor(s): Sidney Hecht, Omar Khdour, Mohammad Alam, Sriloy Dey, Yana Chen, Arnaud Chevalier
Keywords(s): Alzheimer's Disease, Drug Discovery, Mitochondrial medicine, Neurodegenerative Disorders
Category(s): Life Science (All LS Techs), Pharmaceuticals, Non-Cancer Therapeutics
Alkylaminoquinones as Multifunctional Radical Quenchers
Mitochondrial diseases are a group of disorders associated with dysfunctional mitochondria, often caused by genetic mutations to mitochondrial DNA. Mitochondrial defects are damaging, particularly to tissues with high energy demands such as neural and muscle tissues. Energetic defects have been implicated in forms of movement disorders, cardiomyopathy,...
Published: 2/26/2026   |   Inventor(s): Sidney Hecht, Manikandadas Mathilakathu Madathil, Omar Khdour
Keywords(s): Alzheimer's Disease, CNS Therapeutics, Drug, Mitochondrial medicine, Neurodegenerative Disorders, Neurological Disorders, Pharmaceutical, Therapeutics
Category(s): Life Science (All LS Techs), Non-Cancer Therapeutics, Pharmaceuticals
1 2